Francis Knuettel II's Form 4 filing
Pelthos Therapeutics Inc. (PTHS) · filed Sep 12, 2024
- Accession no.
- 0001753926-24-001570
- Filed
- Sep 12, 2024
- Trade date
- Sep 10-11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $11.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Francis Knuettel IICIK 0001433316 | Officer (CEO, Pres., CFO, Treas & Secty) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This sale price represents the weighted average sale price of the shares purchased ranging from $0.80 to $0.92 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
Referenced by the price of 1 transaction in Table I.
- F2
This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This sale price represents the weighted average sale price of the shares purchased ranging from $0.89 to $0.98 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
Referenced by the price of 1 transaction in Table I.